Prognostic biomarkers in phase II trial of cetuximab-containing induction and chemoradiation in resectable HNSCC: Eastern Cooperative Oncology Group E2303

PURPOSE: We sought to evaluate correlation between tissue biomarker expression (using standardized, quantitative immunofluorescence) and clinical outcome in E2303 trial. EXPERIMENTAL DESIGN: Sixty-three eligible patients with operable stage III/IV HNSCC participated in ECOG 2303, phase II trial of i...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Psyrri, Amanda, Lee, Ju-Whei, Pectasides, Eirini, Vassilakopoulou, Maria, Kosmidis, Efstratios K., Burtness, Barbara A., Rimm, David L., Wanebo, Harold J., Forastiere, Arlene A.
Formato: Artigo
Lenguaje:Inglês
Publicado: 2014
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4049169/
https://ncbi.nlm.nih.gov/pubmed/24700741
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-14-0113
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares